First-line chemotherapy with liposomal doxorubicin plus cisplatin for patients with advanced malignant pleural mesothelioma: Phase II trial

British Journal of Cancer

Volumn 106, Issue 6, 2012, Pages 1027-1032

  Arrieta, O ^a,b   Medina, L A ^c   Estrada Lobato, E ^b   Hernandez Pedro N ^b   Villanueva Rodriguez G ^b   Martinez Barrera L ^d   MacEdo, E O ^a   Lopez Rodriguez V ^c   Motola Kuba, D ^a   Corona Cruz, J F ^a  

^a Mexico Vasco de Quiroga # 15   (Mexico)

^b INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^c UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^d INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

Author keywords

cisplatin; LD radiolabelling; liposomal doxorubicin; malignant pleural mesothelioma; Phase II; quallity life

Indexed keywords

APREPITANT; CARBOPLATIN; CISPLATIN; CREATININE; DEXAMETHASONE; DOXORUBICIN; GEMCITABINE; NAVELBINE; ONDANSETRON; PEMETREXED; TECHNETIUM 99M;

ADVANCED CANCER; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; CLINICAL ARTICLE; CONSTIPATION; COUGHING; DIARRHEA; DRUG ACCUMULATION; DRUG FATALITY; DRUG LIVER LEVEL; DRUG SAFETY; DRUG SUBSTITUTION; DRUG UPTAKE; DRUG WITHDRAWAL; DYSPNEA; EORTC QUALITY OF LIFE QUESTIONNAIRE; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; INOPERABLE CANCER; ISOTOPE LABELING; LEUKOPENIA; LIMB PAIN; LYMPHOCYTOPENIA; MALE; MALIGNANT MESOTHELIOMA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PHYSICAL ACTIVITY; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; QUESTIONNAIRE; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOFT TISSUE; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT RESPONSE; WHOLE BODY SCINTISCANNING;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIPOSOMES; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURAL NEOPLASMS; QUALITY OF LIFE; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 84858280990     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.44     Document Type: Article

References (37)

1. Antman KH (1980) Current concepts: malignant mesothelioma. N Engl J Med 303: 200-202
2. Ardizzoni A, Rosso R, Salvati F, Fusco V, Cinquegrana A, De Palma M, Serrano J, Pennucci MC, Soresi E, Crippa M, Gulisano M, Castagneto B, Scagliotti G, Rinaldi M (1991) Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma. An Italian Lung Cancer Task Force (FONICAP) Phase II study. Cancer 67: 2984-2987
3. Ashcroft T (1973) Epidemiological and quantitative relationships between mesothelioma and asbestos on Tyneside. J Clin Pathol 26: 832-840
4. Baas P, van Meerbeeck J, Groen H, Schouwink H, Burgers S, Daamen S, Giaccone G (2000) Caelyx in malignant mesothelioma: a phase II EORTC study. Ann Oncol 11: 697-700
5. Baldini EH, Recht A, Strauss GM, DeCamp Jr MM, Swanson SJ, Liptay MJ, Mentzer SJ, Sugarbaker DJ (1997) Patterns of failure after trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg 63: 334-338 (Pubitemid 27084548)
6. Bao A, Goins B, Klipper R, Negrete G, Phillips WT (2004) Direct 99mTc labeling of pegylated liposomal doxorubicin (Doxil) for pharmacokinetic and non-invasive imaging studies. J Pharmacol Exp Ther 308: 419-425 (Pubitemid 38134199)
7. Berghmans T, Paesmans M, Lalami Y, Louviaux I, Luce S, Mascaux C, Meert AP, Sculier JP (2002) Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer 38: 111-121 (Pubitemid 35157753)
8. Byrne MJ, Nowak AK (2004) Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 15: 257-260 (Pubitemid 38262625)
9. Castagneto B, Zai S, Dongiovanni D, Muzio A, Bretti S, Numico G, Botta M, Sinaccio G (2005) Cisplatin and gemcitabine in malignant pleural mesothelioma: a phase II study. J Clin Oncol 28: 223-226 (Pubitemid 40800471)
10. Chahinian AP, Antman K, Goutsou M, Corson JM, Suzuki Y, Modeas C, Herndon II JE, Aisner J, Ellison RR, Leone L, Vogelzang NJ, Green MR (1993) Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B. J Clin Oncol 11: 1559-1565 (Pubitemid 23228263)
11. Connelly RR, Spirtas R, Myers MH, Percy CL, Fraumeni Jr JF (1987) Demographic patterns for mesothelioma in the United States. J Natl Cancer Inst 78: 1053-1060 (Pubitemid 17113635)
12. Cristaudo A, Foddis R, Vivaldi A, Buselli R, Gattini V, Guglielmi G, Cosentino F, Ottenga F, Ciancia E, Libener R, Filiberti R, Neri M, Betta P, Tognon M, Mutti L, Puntoni R (2005) SV40 enhances the risk of malignant mesothelioma among people exposed to asbestos: a molecular epidemiologic case-control study. Cancer Res 65: 3049-3052 (Pubitemid 40524583)
13. de Perrot M, Field R, Cho BC, Bezjak A, Anraku M, Burkes R, Roberts H, Tsao MS, Leighl N, Keshavjee S, Johnston MR (2009) Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol 27: 1413-1418
14. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D (1999) Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 51: 691-743
15. Henss H, Fiebig HH, Schildge J, Arnold H, Hasse J (1988) Phase-II study with the combination of cisplatin and doxorubicin in advanced malignant mesothelioma of the pleura. Onkologie 11: 118-120
16. Hillerdal G, Sorensen JB, Sundstrom S, Vikström A, Hjerpe A (2008a) Treatment of malignant pleural mesothelioma with liposomized doxorubicine: prolonged time to progression and good survival. A Nordic study. Clin Respir J 2: 80-85
17. Hillerdal G, Sorensen JB, Sundstrom S, Riska H, Vikström A, Hjerpe A (2008b) Treatment of malignant pleural mesothelioma with carboplatin, liposomized doxorubicin, and gemcitabine: a phase II study. J Thorac Oncol 3: 1325-1331
18. Hodgson DC, Gilbert ES, Dores GM, Schonfeld SJ, Lynch CF, Storm H, Hall P, Langmark F, Pukkala E, Andersson M, Kaijser M, Joensuu H, Fossa° SD, Travis LB (2007) Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. J Clin Oncol 25: 1489-1497 (Pubitemid 46759253)
19. Kelly RJ, Sharon E, Hassan R (2011) Chemotherapy and targeted therapies for unresectable malignant mesothelioma. Lung Cancer 73: 256-263
20. Kindler HL (2008) Systemic treatments for mesothelioma: standard and novel. Curr Treat Options Oncol 9: 171-179
21. Nicholson WJ, Perkel G, Selikoff IJ (1982) Occupational exposure to asbestos: population at risk and projected mortality-1980-2030. Am J Ind Med 3: 259-311 (Pubitemid 13140969)
22. Northfelt DW, Martin FJ, Working P, Volberding PA, Russell J, Newman M, Amantea MA, Kaplan LD (1996) Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J Clin Pharmacol 36: 55-63 (Pubitemid 26058811)
23. Peto J, Hodgson JT, Matthews FE, Jones JR (1995) Continuing increase in mesothelioma mortality in Britain. Lancet 345: 535-539
24. Prevalencia del mesotelioma pleural en México (2007) (accessed 25 July 2011, at http://www.imfimex.org/wpcontent/uploads/CONFERENCIA %20OMAR%20GARFIAS.pdf )
25. Price B (1997) Analysis of current trends in United States mesothelioma incidence. Am J Epidemiol 145: 211-218
26. Ray M, Kindler HL (2009) Malignant pleural mesothelioma: an update on biomarkers and treatment. Chest 136: 888-896
27. Rizzo P, Carbone M, Fisher SG, Matker C, Swinnen LJ, Powers A, Di Resta I, Alkan S, Pass HI, Fisher RI (1999) Simian virus 40 is present in most United States human mesotheliomas, but it is rarely present in non-Hodgkin's lymphoma. Chest 116(6 Suppl): 470S-473S (Pubitemid 30013160)
28. Skubitz KM (2002) Phase II trial of pegylated-liposomal doxorubicin (Doxil) in mesothelioma. Cancer Invest 20: 693-699 (Pubitemid 37210040)
29. Sorensen JB, Frank H, Palshof T (2008) Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma. Br J Cancer 99: 44-50 (Pubitemid 351920221)
30. Tannock IF, Lee CM, Tunggal JK, Cowan DS, Egorin MJ (2002) Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy. Clin Cancer Res 8: 878-884 (Pubitemid 34742121)
31. Treasure T, Lang-Lazdunski L, Waller D, Bliss JM, Tan C, Entwisle J, Snee M, O'Brien M, Thomas G, Senan S, O'Byrne K, Kilburn LS, Spicer J, Landau D, Edwards J, Coombes G, Darlison L, Peto J (2011) Extra-pleural pneumonectomy vs no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol 12: 763-772
32. Uziely B, Jeffers S, Isacson R, Kutsch K, Wei-Tsao D, Yehoshua Z, Libson E, Muggia FM, Gabizon A (1995) Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 13: 1777-1785
33. van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, Vincent M, Legrand C, Bottomley A, Debruyne C, Giaccone G (2005) Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 23: 6881-6889
34. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P (2003) Phase III study of pemetrexed in combination with cisplatin vs cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21: 2636-2644 (Pubitemid 46606305)
35. Weder W, Stahel RA, Bernhard J, Bodis S, Vogt P, Ballabeni P, Lardinois D, Betticher D, Schmid R, Stupp R, RisHB, JermannM,MingroneW, Roth AD, Spiliopoulos A, Swiss Group for Clinical Cancer Research (2007) Multicenter trial of neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol 18: 1196-1202 (Pubitemid 47244366)
36. Winslow DJ, Taylor HB (1960) Malignant peritoneal mesotheliomas: a clinicopathological analysis of 12 fatal cases. Cancer 13: 127-136
37. Yan TD, Boyer M, Tin MM, Sim J, Kennedy C, McLean J, Bannon PG, McCaughan BC (2009) Prognostic features of long-term survivors after surgical management of malignant pleural mesothelioma. Ann Thorac Surg 87: 1552-1556